 | Up a level |
Reid, DM; Devogelaer, JP; Saag, K; Roux, C; Lau, CS; Reginster, JY; Papanastasiou, P; Ferreira, A; Hartl, F; Fashola, T; Mesenbrink, P; Sambrook, PN; Perrelet, Romain; HORIZON, investigators (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373(9671), pp. 1253-1263. London: Elsevier 10.1016/S0140-6736(09)60250-6
Devogelaer, J P; Brown, J P; Burckhardt, P; Meunier, P J; Goemaere, S; Lippuner, K; Body, J J; Samsioe, G; Felsenberg, D; Fashola, T; Sanna, L; Ortmann, C E; Trechsel, U; Krasnow, J; Eriksen, E F; Garnero, P (2007). Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis international, 18(9), pp. 1211-8. London: Springer 10.1007/s00198-007-0367-3
